AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35970013 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiagent induction chemotherapy (ICT; nab-paclitaxel/gemcitabine alone or nab-paclitaxel/gemcitabine followed by FOLFIRINOX) for 16 weeks
Number of subjects: 165
Study 35970013 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiagent induction chemotherapy (ICT) with robust CA 19-9 response (decrease to ≤50 U/ml)
Number of subjects: 165
Study 35970013 — intervention group
Group type: EXPERIMENTAL
Intervention: R0 resection (n=31; 23%)
Number of subjects: 165
Study 35970013 — intervention group
Group type: EXPERIMENTAL
Intervention: R1 resection (n=14; 11%)
Number of subjects: 165
Study 35970013 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 19-9 response after ICT
Number of subjects: 165
Study 35970013 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 19-9 decrease to ≤61 U/ml as optimal cut-off
Number of subjects: 165
Study 35970013 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 19-9 nonresponders (<20% decrease or increase)
Number of subjects: 165
Study 36224406 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic TaTME
Number of subjects: 116
Study 36224406 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic LaTME
Number of subjects: 116
Study 34031138 — intervention group
Group type: EXPERIMENTAL
Intervention: Veverimer
Number of subjects: 0
Study 32386521 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS+0.5g/kg Gln
Number of subjects: 40
Study 32386521 — intervention group
Group type: COMPARATOR
Intervention: PCOS group
Number of subjects: 40
Study 33779938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 2030
Study 33779938 — intervention group
Group type: COMPARATOR
Intervention: Placebo 10 mg once daily
Number of subjects: 2030
Study 33559973 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedaling for Parkinson's ™ (PFP) program
Number of subjects: 0
Study 36195320 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin mixed with solid lipid curcumin particle (SLCP)
Number of subjects: 10
Study 36195320 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin mixed with squalene (CSQU)
Number of subjects: 10
Study 36195320 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin mixed with docosahexaenoic acid (CDHA)
Number of subjects: 10
Study 36195320 — intervention group
Group type: COMPARATOR
Intervention: Standardized unformulated curcumin extract (StdC)
Number of subjects: 10
Study 32341031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel or cabazitaxel and carboplatin
Number of subjects: 47
Study 32341031 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC analysis
Number of subjects: 47
Study 34710363 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised primaquine treatment (0.5 mg/kg per day for 14 days, supervised on alternate days)
Number of subjects: 419
Study 34710363 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised primaquine treatment (0.5 mg/kg per day for 14 days, unsupervised)
Number of subjects: 419
Study 34710363 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised primaquine treatment
Number of subjects: 419
Study 34710363 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised primaquine treatment
Number of subjects: 419
Study 33555626 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based documents (VRdocs)
Number of subjects: 77
Study 33555626 — intervention group
Group type: COMPARATOR
Intervention: Control group education documents
Number of subjects: 77
Study 36196180 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydroxyurea
Number of subjects: 20000
Study 36196180 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose hydroxyurea
Number of subjects: 20000
Study 36196180 — intervention group
Group type: EXPERIMENTAL
Intervention: State-supported stroke screening service and treatment
Number of subjects: 20000
Study 33693945 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA-rich meals
Number of subjects: 32
Study 33693945 — intervention group
Group type: COMPARATOR
Intervention: SFA-rich meals
Number of subjects: 32
Study 33693945 — intervention group
Group type: COMPARATOR
Intervention: n-6 PUFA-rich meals
Number of subjects: 32
Study 32689849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer’s lactate (RL) group
Number of subjects: 96
Study 32689849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) group
Number of subjects: 96
Study 35363161 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (40 sessions for 16 weeks with usual care)
Number of subjects: 60
Study 35363161 — intervention group
Group type: COMPARATOR
Intervention: Usual care (regular meals, sufficient sleep, and appropriate exercise)
Number of subjects: 60
Study 33327727 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-controlled antidiabetic or antiplatelet medications
Number of subjects: 10
Study 33327727 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled antidiabetic or antiplatelet medications
Number of subjects: 10
Study 33327727 — intervention group
Group type: EXPERIMENTAL
Intervention: Active comparators
Number of subjects: 10
Study 33327727 — intervention group
Group type: COMPARATOR
Intervention: Second-generation sulfonylureas as a proxy for placebo
Number of subjects: 10
Study 33327727 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall RWE findings
Number of subjects: 10
Study 36053298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral OXT (24IU)
Number of subjects: 80
Study 33356529 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg/day) plus androgen deprivation therapy
Number of subjects: 1146
Study 33356529 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus androgen deprivation therapy
Number of subjects: 1146
Study 34775518 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0% hydrogen peroxide (HP)
Number of subjects: 64
Study 34775518 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% hydrogen peroxide (HP) + Germinator
Number of subjects: 64
Study 34775518 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0% hydrogen peroxide (HP) + Germinator
Number of subjects: 64
Study 34775518 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX) + Germinator
Number of subjects: 64
Study 34775518 — intervention group
Group type: EXPERIMENTAL
Intervention: Germinator
Number of subjects: 64
Study 34775518 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 64
Study 34775518 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% hydrogen peroxide (HP)
Number of subjects: 64
Study 34775518 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX)
Number of subjects: 64
Study 33351921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle therapy plus testosterone (LT+Test)
Number of subjects: 83
Study 33351921 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle therapy plus placebo (LT+Pbo)
Number of subjects: 83
Study 35594514 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 13
Study 35594514 — intervention group
Group type: COMPARATOR
Intervention: Flexible fixation
Number of subjects: 13
Study 35594514 — intervention group
Group type: COMPARATOR
Intervention: Uninjured ankles
Number of subjects: 13
Study 33300209 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-Rich Platelet-Rich Plasma
Number of subjects: 0
Study 33300209 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid
Number of subjects: 0
Study 32174449 — intervention group
Group type: EXPERIMENTAL
Intervention: Running at 8 km/h
Number of subjects: 31
Study 32174449 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive runners
Number of subjects: 31
Study 32174449 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational runners
Number of subjects: 31
Study 32174449 — intervention group
Group type: EXPERIMENTAL
Intervention: Novice runners
Number of subjects: 31
Study 32174449 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 31
Study 36347265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose
Number of subjects: 1137
Study 36347265 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1137
Study 34769633 — intervention group
Group type: EXPERIMENTAL
Intervention: EVOO + DieTBra
Number of subjects: 149
Study 34769633 — intervention group
Group type: EXPERIMENTAL
Intervention: DieTBra
Number of subjects: 149
Study 34769633 — intervention group
Group type: EXPERIMENTAL
Intervention: EVOO
Number of subjects: 149
Study 33361029 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg every 12 hours)
Number of subjects: 60
Study 33361029 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (20 mg once daily for 2 weeks)
Number of subjects: 60
Study 35717989 — intervention group
Group type: EXPERIMENTAL
Intervention: Liso-cel (100 × 10^6 CAR+ T cells intravenously)
Number of subjects: 184
Study 35717989 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (salvage immunochemotherapy followed by autologous HSCT)
Number of subjects: 184
Study 35717989 — intervention group
Group type: EXPERIMENTAL
Intervention: Liso-cel
Number of subjects: 184
Study 35717989 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 184
Study 32445215 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC group (Microwave ablation combined with cisplatin plus gemcitabine)
Number of subjects: 100
Study 32445215 — intervention group
Group type: COMPARATOR
Intervention: MGC group (Microwave ablation combined with gemcitabine plus pemetrexed)
Number of subjects: 100
Study 34118301 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula (AVF)
Number of subjects: 19867
Study 34118301 — intervention group
Group type: COMPARATOR
Intervention: Arteriovenous graft (AVG)
Number of subjects: 19867
Study 34898943 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation and breathing exercises
Number of subjects: 84
Study 34898943 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 84
Study 34677081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit and Facebook-based PA intervention
Number of subjects: 50
Study 34677081 — intervention group
Group type: COMPARATOR
Intervention: Fitbit only (Control)
Number of subjects: 50
Study 32954942 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (N = 128)
Number of subjects: 245
Study 32954942 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (N = 117)
Number of subjects: 245
Study 34016085 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine antenatal screening ultrasound (US)
Number of subjects: 0
Study 34016085 — intervention group
Group type: COMPARATOR
Intervention: Non-ultrasound ANC visits
Number of subjects: 0
Study 34016085 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-risk pregnancies
Number of subjects: 0
Study 34016085 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal screening US
Number of subjects: 0
Study 32514820 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g or 30 g 10% trehalose solution administered weekly via IV
Number of subjects: 14
Study 35094377 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy (LSCP)
Number of subjects: 32
Study 35094377 — intervention group
Group type: COMPARATOR
Intervention: Sacrospinous ligament fixation (SSLF)
Number of subjects: 32
Study 35080016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele‐Savvy (active condition)
Number of subjects: 111
Study 35080016 — intervention group
Group type: COMPARATOR
Intervention: Healthy Living (attention control)
Number of subjects: 111
Study 35080016 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 111
Study 32285809 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 110
Study 32285809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (TOF)
Number of subjects: 110
Study 32285809 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy (ST)
Number of subjects: 110
Study 32285809 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 110
Study 35899435 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6-guided opioid prescribing with clinical decision support (CDS) for postoperative pain management (intervention arm)
Number of subjects: 2020
Study 35899435 — intervention group
Group type: COMPARATOR
Intervention: Delayed testing without clinical decision support (control arm)
Number of subjects: 2020
Study 35899435 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6-guided opioid prescribing (intervention arm)
Number of subjects: 2020
Study 34063665 — intervention group
Group type: EXPERIMENTAL
Intervention: High Volume (HV: 5 sets of 10 reps at 70% of 1 repetition maximum (1RM))
Number of subjects: 11
Study 34063665 — intervention group
Group type: COMPARATOR
Intervention: High Intensity (HI: 5 sets of 3 reps at 90% of 1RM)
Number of subjects: 11
Study 34063665 — intervention group
Group type: EXPERIMENTAL
Intervention: High Volume (HV)
Number of subjects: 11
Study 34063665 — intervention group
Group type: COMPARATOR
Intervention: High Intensity (HI)
Number of subjects: 11
Study 32947423 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine + nalbuphine
Number of subjects: 48
Study 32947423 — intervention group
Group type: COMPARATOR
Intervention: levobupivacaine + dexmedetomidine
Number of subjects: 48
Study 35172587 — intervention group
Group type: EXPERIMENTAL
Intervention: Xevinapant plus standard‐of‐care cisplatin‐based chemoradiotherapy (CRT)
Number of subjects: 700
Study 35172587 — intervention group
Group type: EXPERIMENTAL
Intervention: Xevinapant monotherapy
Number of subjects: 700
Study 35172587 — intervention group
Group type: COMPARATOR
Intervention: Xevinapant or placebo plus standard‐of‐care CRT
Number of subjects: 700
Study 34574676 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% O2
Number of subjects: 22
Study 34574676 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% O2
Number of subjects: 22
Study 34574676 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2 (HBO) at 1.5 ATA
Number of subjects: 22
Study 34574676 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2 (HBO) at 2.5 ATA
Number of subjects: 22
Study 34574676 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 36067925 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE)
Number of subjects: 47
Study 36067925 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (EA)
Number of subjects: 47
Study 34226496 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medications associated with weight gain
Number of subjects: 366
Study 34226496 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medications with high risk of weight gain
Number of subjects: 366
Study 34226496 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational attainment (EA) as a proxy for SES
Number of subjects: 366
Study 32618247 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DHAP) administered in four rounds of mass drug administration (MDA)
Number of subjects: 0
Study 32618247 — intervention group
Group type: COMPARATOR
Intervention: Standard of care without any mass treatment
Number of subjects: 0
Study 35882260 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 187
Study 35882260 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 187
Study 32112077 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization-based confidence intervals using individual-level data from a CRT
Number of subjects: 0
Study 32112077 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization test for obtaining confidence intervals
Number of subjects: 0
Study 32112077 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method for randomization-based CIs
Number of subjects: 0
Study 32891607 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (PSD)
Number of subjects: 20
Study 32891607 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep night (CONT)
Number of subjects: 20
Study 35338833 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of relatives during home visits by a geriatric team
Number of subjects: 437
Study 35338833 — intervention group
Group type: COMPARATOR
Intervention: No involvement of relatives during home visits by a geriatric team
Number of subjects: 437
Study 34405423 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiPole Pacing (MPP) therapy
Number of subjects: 53
Study 34175944 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing orders for syphilis serological testing with viral loads
Number of subjects: 3895
Study 34175944 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 3895
Study 33095965 — intervention group
Group type: EXPERIMENTAL
Intervention: EJV-based landmark (EJV-LM) approach
Number of subjects: 188
Study 33095965 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US)-guided approach
Number of subjects: 188
Study 32215583 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT plus high-dose nonsteroidal antiandrogen (bicalutamide, 150 mg/d) for 2 years
Number of subjects: 760
Study 32215583 — intervention group
Group type: COMPARATOR
Intervention: SRT plus placebo for 2 years
Number of subjects: 760
Study 35291282 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 with MAG-OM3
Number of subjects: 30
Study 35291282 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 with rice oil
Number of subjects: 30
Study 35291282 — intervention group
Group type: COMPARATOR
Intervention: CoQ10 alone
Number of subjects: 30
Study 34011271 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) at baseline
Number of subjects: 0
Study 34011271 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study 32315070 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 2 pivotal trials
Number of subjects: 273
Study 32315070 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-group pivotal trials
Number of subjects: 273
Study 32315070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivotal trials of 6 months' duration
Number of subjects: 273
Study 36329722 — intervention group
Group type: EXPERIMENTAL
Intervention: Aframomum melegueta seed extract (AfperFit) 250 mg, twice daily for 12 weeks
Number of subjects: 70
Study 36329722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 32533332 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral triangle block (FT)
Number of subjects: 98
Study 32533332 — intervention group
Group type: COMPARATOR
Intervention: Adductor canal block (AC)
Number of subjects: 98
Study 32533332 — intervention group
Group type: COMPARATOR
Intervention: Functional mobility (TUG test)
Number of subjects: 98
Study 35831693 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training (PT) intervention (n = 60)
Number of subjects: 119
Study 35831693 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational toolkit (n = 59)
Number of subjects: 119
Study 34468709 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex PCI
Number of subjects: 3377
Study 34468709 — intervention group
Group type: COMPARATOR
Intervention: Non-complex PCI
Number of subjects: 3377
Study 33037808 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol–malic acid tablets (as a supplement to omeprazole 40 mg/day)
Number of subjects: 14
Study 35118156 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived stromal vascular fractions (SVF) injections
Number of subjects: 0
Study 35118156 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) injections
Number of subjects: 0
Study 34001168 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic supplementation (E, n=11)
Number of subjects: 27
Study 34001168 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (C, n=16)
Number of subjects: 27
Study 34332547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral oxygenation monitoring treatment
Number of subjects: 818
Study 34332547 — intervention group
Group type: COMPARATOR
Intervention: Monitoring and treatment as usual
Number of subjects: 818
Study 32472875 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate addition of nasal stent
Number of subjects: 20
Study 32472875 — intervention group
Group type: COMPARATOR
Intervention: Delayed addition of nasal stent
Number of subjects: 20
Study 33876259 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen before exercise (IP)
Number of subjects: 42
Study 33876259 — intervention group
Group type: COMPARATOR
Intervention: Placebo before and ibuprofen after exercise (PI)
Number of subjects: 42
Study 33876259 — intervention group
Group type: COMPARATOR
Intervention: Placebo before and after exercise (PP)
Number of subjects: 42
Study 32545223 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with toluidine blue O and LED light, applied at baseline and 3-months in addition to non-surgical periodontal treatment
Number of subjects: 36
Study 32545223 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical periodontal treatment
Number of subjects: 36
Study 35450527 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus olfactory training
Number of subjects: 185
Study 34800400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cipaglucosidase alfa plus miglustat
Number of subjects: 125
Study 34800400 — intervention group
Group type: COMPARATOR
Intervention: Alglucosidase alfa plus placebo
Number of subjects: 125
Study 32571859 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme (12-week tailored programme with weekly telephone calls for exercise progression)
Number of subjects: 0
Study 32571859 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme
Number of subjects: 0
Study 32571859 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 35546694 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatine-based model training (Group 1: n: 26)
Number of subjects: 48
Study 35546694 — intervention group
Group type: COMPARATOR
Intervention: No model training (Group 2: n: 22)
Number of subjects: 48
Study 33839477 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the ASQ‐3 (18‐ to 54‐month questionnaires)
Number of subjects: 4016
Study 33839477 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the ASQ‐3
Number of subjects: 4016